TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to find out if the investigational drug Ribociclib (LEE011), when taken with standard treatment (Tamoxifen +/- Goserelin) is safe and has beneficial effects in pre-menopausal and post-menopausal women and men who have a type of breast cancer known as hormone receptor positive/HER2- breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Phase I Dose Escalation:
The phase I portion of the study is a dose escalation to confirm the safety of the combination and to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) for ribociclib with Tamoxifen.
Phase I will be conducted in all participants with Hormone Receptor Positive (HR+)/Human Epidermal growth factor Receptor 2 Negative (HER2-) locally advanced or metastatic breast cancer with any prior endocrine therapy and up to three prior cytotoxic chemotherapy regimens administered in the metastatic or locally advanced setting.
Phase Ib Dose Expansion:
Phase I trials are increasingly including dose-expansion cohorts (Ib) after the maximum-tolerated dose has been reached to better characterize the toxicity profile and identify early signs of efficacy within this specific disease population. The investigators' goal is to assess the anti-tumor activity Ribociclib + Tamoxifen and to further evaluate their safety in adult patients with HR+/HER2- locally advanced or metastatic breast cancer. Patients in the phase 1b expansion will have the same exclusion and inclusion criteria except that they will only be allowed to have up to two lines of cytotoxic chemotherapy in the metastatic setting.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tamoxifen and Ribociclib with Goserelin Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle. |
Drug: Tamoxifen
Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
Drug: Ribociclib
Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a "rest" period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD).
Other Names:
Drug: Goserelin
Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Recommended Phase II Dose (RP2D) [Up to 12 months]
400-600 mg of Ribociclib, when taken with Tamoxifen 20 mg. The Phase I portion of the study is a dose escalation to confirm the dose limiting toxicity (DLT) and the RP2D for ribociclib with Tamoxifen. DLT is defined as an adverse event or abnormal laboratory value assessed as having a reasonable possibility related to the study medication, unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) with LEE011 and Tamoxifen. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading. In this study, a DLT will occur if CTCAE grade 4 neutropenia lasts more than 4 consecutive days, if CTCAE grade 3 thrombocytopenia is associated with clinically significant bleeding or if there is grade 4 thrombocytopenia.
Secondary Outcome Measures
- Progression-free Survival (PFS) at Six Months [6 months]
Occurrence of Progression Survival at 6 months. PFS: On study date to date of progression or the same as overall survival time if not progressed. Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
- Overall Survival (OS) at Six Months [6 months]
Occurrence of Overall Survival at 6 months. OS: On study date to expired date or last visit date if not deceased.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically and/or cytologically confirmed diagnosis of Estrogen Receptor-Positive (ER+) and/or Progesterone Receptor-Positive (PR+) breast cancer by local laboratory.
-
Human Epidermal growth factor Receptor 2 Negative (HER2-) breast cancer defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative In Situ Hybridization (Fluorescence [FISH], Chromogenic [CISH], or Silver [SISH]) test is required by local laboratory testing.
-
Participants are allowed (but not required) to have up to two lines of prior chemotherapy regimens in the metastatic setting for the dose expansion phase. For the dose escalation cohort, up to three previous lines of chemotherapy in the metastatic setting is acceptable.
-
Measurable disease, i.e., at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria only *for expansion cohorts.
-
For *escalation cohorts, bone only disease is allowed. For expansion cohorts, there must be measurable disease as stated above.
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
-
Written informed consent must be obtained prior to any screening procedures and according to local guidelines.
-
Adequate bone marrow and organ function.
-
Must be able to swallow ribociclib and Tamoxifen capsules/tablets.
-
Pre-Menopausal Women Eligibility: 1) Pre-menopausal women who received adjuvant Aromatase Inhibitor and Ovarian Suppression (AI + OS) in the adjuvant setting and completed at least 12 months of hormonal therapy. 2) Pre-menopausal women with de novo metastatic disease are eligible if they have had no prior endocrine therapy. 3) Pre-menopausal women who have not received Tamoxifen in the metastatic setting, but have received up to two lines of chemotherapy.
-
Post-Menopausal Women and Men Eligibility: 1) Post-menopausal women or men who have progressed on first-line or second line therapy with an aromatase inhibitor in the metastatic setting. 2) Post-menopausal women or men who have recurred while on or after completion of adjuvant treatment with aromatase inhibitors (they have completed at least one year of AI in the adjuvant setting before progression on AI). 3) Post-menopausal women or men who are not considered candidates for treatment with an aromatase inhibitory by their oncologist, patients not willing to go on AI, or patients who were intolerant to AI.
-
Post-menopausal women or men are allowed (but not required) to have up to two lines of prior chemotherapy regimens in the metastatic setting for the dose expansion phase . For the dose escalation cohort, up to three previous lines of chemotherapy in the metastatic setting is acceptable.
Exclusion Criteria:
-
Potential participants with inflammatory breast cancer.
-
Prior CDK 4/6 inhibitor exposure.
-
Have received Tamoxifen in the metastatic setting (for more than 30 days) or has progressed while on Tamoxifen in the adjuvant setting.
-
Known hypersensitivity to ribociclib or excipients of tamoxifen.
-
A concurrent malignancy or malignancy within 3 years of starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
-
Central nervous system (CNS) involvement unless specific criteria are met.
-
Impairment of Gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
-
Known history of HIV infection (testing not mandatory).
-
Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
-
Clinically significant, uncontrolled heart disease and/or a recent events as specified in the study protocol
-
Currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug: a. Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges.
- That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. c. That have a known risk to prolong the QT interval or induce Torsades de Pointes. d. Herbal preparations/medications, dietary supplements not prescribed by an M.D..
-
Currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment.
-
The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).
-
Currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
-
Participation in a prior investigational study within 30 days prior to enrollment..
-
Has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥ 25% of the bone marrow was irradiated.
-
Has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).
-
Has not recovered from all toxicities related to prior anticancer therapies to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grade equal to or less than 1 (Exception to this criterion: patients with any grade of alopecia are allowed to enter the study).
-
A Child-Pugh score B or C.
-
History of non-compliance to medical regimen or inability to grant consent.
-
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.]
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 12 weeks after study drug discontinuation. There are specific guidelines regarding the various acceptable highly effective contraception methods. Note: The use of oral contraception is not allowed.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | United States | 33612 |
Sponsors and Collaborators
- H. Lee Moffitt Cancer Center and Research Institute
- Novartis
Investigators
- Principal Investigator: Roohi Ismail-Khan, MD, MSc, H. Lee Moffitt Cancer Center and Research Institute
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- MCC-18332
Study Results
Participant Flow
| Recruitment Details | Participants were enrolled at Moffitt Cancer Center March 2016 through September 2016. All participants were enrolled and treated on Cohort 1 (Ribociclib 400 mg PO D1-21; Tamoxifen 20 mg PO QD (1) only. |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin |
|---|---|
| Arm/Group Description | Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle. Tamoxifen: Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle). Ribociclib: Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a "rest" period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD). Goserelin: Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women. |
| Period Title: Overall Study | |
| STARTED | 7 |
| COMPLETED | 7 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin |
|---|---|
| Arm/Group Description | Phase I dose escalation followed by Phase Ib dose expansion. |
| Overall Participants | 7 |
| Age (years) [Median (Standard Deviation) ] | |
| Median (Standard Deviation) [years] |
54
(13.31)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
7
100%
|
| Male |
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
1
14.3%
|
| White |
6
85.7%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
0
0%
|
| Region of Enrollment (participants) [Number] | |
| United States |
7
100%
|
Outcome Measures
| Title | Recommended Phase II Dose (RP2D) |
|---|---|
| Description | 400-600 mg of Ribociclib, when taken with Tamoxifen 20 mg. The Phase I portion of the study is a dose escalation to confirm the dose limiting toxicity (DLT) and the RP2D for ribociclib with Tamoxifen. DLT is defined as an adverse event or abnormal laboratory value assessed as having a reasonable possibility related to the study medication, unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) with LEE011 and Tamoxifen. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading. In this study, a DLT will occur if CTCAE grade 4 neutropenia lasts more than 4 consecutive days, if CTCAE grade 3 thrombocytopenia is associated with clinically significant bleeding or if there is grade 4 thrombocytopenia. |
| Time Frame | Up to 12 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants |
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin |
|---|---|
| Arm/Group Description | Phase I dose escalation followed by Phase Ib dose expansion. |
| Measure Participants | 7 |
| Number [dose in mg] |
400
|
| Title | Progression-free Survival (PFS) at Six Months |
|---|---|
| Description | Occurrence of Progression Survival at 6 months. PFS: On study date to date of progression or the same as overall survival time if not progressed. Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Time Frame | 6 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants. |
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin |
|---|---|
| Arm/Group Description | Phase I dose escalation followed by Phase Ib dose expansion. |
| Measure Participants | 7 |
| Number (95% Confidence Interval) [percentage of participants] |
57.1
815.7%
|
| Title | Overall Survival (OS) at Six Months |
|---|---|
| Description | Occurrence of Overall Survival at 6 months. OS: On study date to expired date or last visit date if not deceased. |
| Time Frame | 6 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants. |
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin |
|---|---|
| Arm/Group Description | Phase I dose escalation followed by Phase Ib dose expansion. |
| Measure Participants | 7 |
| Number (95% Confidence Interval) [percentage of participants] |
83.3
1190%
|
Adverse Events
| Time Frame | 1 year, 2 months | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Tamoxifen and Ribociclib With Goserelin | |
| Arm/Group Description | All participants were enrolled and treated on Cohort 1 (Ribociclib 400 mg PO D1-21; Tamoxifen 20 mg PO QD (1) only. | |
All Cause Mortality |
||
| Tamoxifen and Ribociclib With Goserelin | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/7 (0%) | |
Serious Adverse Events |
||
| Tamoxifen and Ribociclib With Goserelin | ||
| Affected / at Risk (%) | # Events | |
| Total | 2/7 (28.6%) | |
| Gastrointestinal disorders | ||
| Gastrointestinal - Other, Gastroenteritis | 1/7 (14.3%) | 1 |
| General disorders | ||
| Fatigue | 1/7 (14.3%) | 1 |
| Nervous system disorders | ||
| Syncope | 1/7 (14.3%) | 3 |
| Vascular disorders | ||
| Thromboembolic event | 1/7 (14.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Tamoxifen and Ribociclib With Goserelin | ||
| Affected / at Risk (%) | # Events | |
| Total | 7/7 (100%) | |
| Blood and lymphatic system disorders | ||
| Anemia | 1/7 (14.3%) | 1 |
| Cardiac disorders | ||
| Cardiac disorders - Other, T Wave Inversion, Q Wave in II, on EKG | 1/7 (14.3%) | 1 |
| Chest pain - cardiac | 1/7 (14.3%) | 1 |
| Sinus bradycardia | 1/7 (14.3%) | 1 |
| Eye disorders | ||
| Eyelid function disorder | 1/7 (14.3%) | 1 |
| Gastrointestinal disorders | ||
| Vomiting | 2/7 (28.6%) | 2 |
| Constipation | 1/7 (14.3%) | 1 |
| Diarrhea | 1/7 (14.3%) | 2 |
| Dyspepsia | 1/7 (14.3%) | 1 |
| Flatulence | 1/7 (14.3%) | 1 |
| Mucositis oral | 1/7 (14.3%) | 1 |
| General disorders | ||
| Pain | 2/7 (28.6%) | 2 |
| Non-cardiac chest pain | 1/7 (14.3%) | 1 |
| Infections and infestations | ||
| Otitis media | 1/7 (14.3%) | 1 |
| Sinusitis | 1/7 (14.3%) | 1 |
| Upper respiratory infection | 1/7 (14.3%) | 2 |
| Urinary tract infection | 1/7 (14.3%) | 1 |
| Injury, poisoning and procedural complications | ||
| Fall | 1/7 (14.3%) | 1 |
| Fracture | 1/7 (14.3%) | 1 |
| Investigations | ||
| Neutrophil count decreased | 4/7 (57.1%) | 9 |
| White blood cell decreased | 4/7 (57.1%) | 8 |
| Alanine aminotransferase increased | 3/7 (42.9%) | 9 |
| Aspartate aminotransferase increased | 3/7 (42.9%) | 9 |
| Platelet count decreased | 3/7 (42.9%) | 3 |
| Electrocardiogram QT corrected interval prolonged | 2/7 (28.6%) | 5 |
| Alkaline phosphatase increased | 1/7 (14.3%) | 1 |
| Cholesterol high | 1/7 (14.3%) | 1 |
| Creatinine increased | 1/7 (14.3%) | 1 |
| Weight loss | 1/7 (14.3%) | 1 |
| Metabolism and nutrition disorders | ||
| Dehydration | 3/7 (42.9%) | 4 |
| Hypomagnesemia | 2/7 (28.6%) | 2 |
| Anorexia | 1/7 (14.3%) | 1 |
| Hypokalemia | 1/7 (14.3%) | 2 |
| Hypophosphatemia | 1/7 (14.3%) | 3 |
| Musculoskeletal and connective tissue disorders | ||
| Arthralgia | 1/7 (14.3%) | 1 |
| Back pain | 1/7 (14.3%) | 1 |
| Bone pain | 1/7 (14.3%) | 1 |
| Flank pain | 1/7 (14.3%) | 1 |
| Generalized muscle weakness | 1/7 (14.3%) | 2 |
| Myalgia | 1/7 (14.3%) | 1 |
| Nervous system disorders | ||
| Dizziness | 2/7 (28.6%) | 2 |
| Dysgeusia | 1/7 (14.3%) | 1 |
| Neuralgia | 1/7 (14.3%) | 1 |
| Syncope | 1/7 (14.3%) | 1 |
| Renal and urinary disorders | ||
| Acute kidney injury | 1/7 (14.3%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Allergic rhinitis | 1/7 (14.3%) | 1 |
| Cough | 1/7 (14.3%) | 1 |
| Dyspnea | 1/7 (14.3%) | 1 |
| Laryngeal inflammation | 1/7 (14.3%) | 1 |
| Sore throat | 1/7 (14.3%) | 1 |
| Vascular disorders | ||
| Hypotension | 1/7 (14.3%) | 4 |
| Lymphedema | 1/7 (14.3%) | 2 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Hatem Soliman |
|---|---|
| Organization | H. Lee Moffitt Cancer Center and Research Institute |
| Phone | 813-745-4933 |
| hatem.soliman@moffitt.org |
- MCC-18332